Concepts (309)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 20 | 2023 | 248 | 3.020 |
Why?
|
| Neoplasms | 17 | 2023 | 1033 | 2.240 |
Why?
|
| Puerto Rico | 36 | 2023 | 1352 | 2.190 |
Why?
|
| Papillomavirus Infections | 18 | 2022 | 316 | 2.130 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2022 | 29 | 1.100 |
Why?
|
| Early Detection of Cancer | 7 | 2023 | 292 | 1.020 |
Why?
|
| Papillomaviridae | 8 | 2015 | 125 | 0.990 |
Why?
|
| Papillomavirus Vaccines | 3 | 2022 | 136 | 0.970 |
Why?
|
| Terminal Care | 2 | 2021 | 47 | 0.970 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 18 | 0.900 |
Why?
|
| Registries | 5 | 2019 | 330 | 0.840 |
Why?
|
| Hospice Care | 1 | 2021 | 14 | 0.810 |
Why?
|
| Humans | 74 | 2023 | 34853 | 0.790 |
Why?
|
| Female | 61 | 2023 | 19873 | 0.790 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 82 | 0.750 |
Why?
|
| Vaginal Smears | 7 | 2013 | 52 | 0.730 |
Why?
|
| United States | 16 | 2023 | 3894 | 0.720 |
Why?
|
| Breast Neoplasms | 9 | 2022 | 1426 | 0.710 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 35 | 0.690 |
Why?
|
| Aged | 29 | 2023 | 6448 | 0.680 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 336 | 0.660 |
Why?
|
| Adult | 42 | 2023 | 11034 | 0.650 |
Why?
|
| Middle Aged | 38 | 2023 | 9642 | 0.570 |
Why?
|
| Patient Acceptance of Health Care | 7 | 2023 | 375 | 0.540 |
Why?
|
| Health Knowledge, Attitudes, Practice | 7 | 2022 | 790 | 0.520 |
Why?
|
| Young Adult | 17 | 2021 | 4012 | 0.520 |
Why?
|
| Sunscreening Agents | 1 | 2014 | 9 | 0.510 |
Why?
|
| Adolescent | 19 | 2021 | 5035 | 0.510 |
Why?
|
| Sunlight | 1 | 2014 | 46 | 0.500 |
Why?
|
| Risk Factors | 11 | 2022 | 3414 | 0.490 |
Why?
|
| Retrospective Studies | 10 | 2022 | 1961 | 0.470 |
Why?
|
| Self Administration | 1 | 2013 | 41 | 0.460 |
Why?
|
| Health Behavior | 3 | 2023 | 491 | 0.460 |
Why?
|
| Specimen Handling | 1 | 2013 | 49 | 0.450 |
Why?
|
| Ambulatory Care | 1 | 2013 | 76 | 0.430 |
Why?
|
| Environmental Exposure | 1 | 2014 | 207 | 0.430 |
Why?
|
| Medicare | 3 | 2022 | 188 | 0.420 |
Why?
|
| Genetic Testing | 1 | 2011 | 71 | 0.400 |
Why?
|
| Incidence | 10 | 2021 | 882 | 0.390 |
Why?
|
| SEER Program | 4 | 2019 | 87 | 0.380 |
Why?
|
| Palliative Care | 2 | 2021 | 52 | 0.370 |
Why?
|
| Information Seeking Behavior | 1 | 2010 | 23 | 0.360 |
Why?
|
| Health Personnel | 2 | 2022 | 200 | 0.350 |
Why?
|
| Uterine Cervical Dysplasia | 5 | 2007 | 38 | 0.340 |
Why?
|
| DNA, Viral | 6 | 2015 | 295 | 0.330 |
Why?
|
| Attitude to Health | 2 | 2011 | 311 | 0.320 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 413 | 0.320 |
Why?
|
| Health Services Accessibility | 6 | 2021 | 531 | 0.310 |
Why?
|
| Language | 2 | 2021 | 143 | 0.310 |
Why?
|
| Endometrial Neoplasms | 4 | 2011 | 64 | 0.300 |
Why?
|
| Cancer Care Facilities | 2 | 2010 | 15 | 0.290 |
Why?
|
| Health Status Disparities | 3 | 2019 | 583 | 0.290 |
Why?
|
| Communication Barriers | 1 | 2006 | 53 | 0.280 |
Why?
|
| Male | 19 | 2022 | 18870 | 0.270 |
Why?
|
| Decision Making | 2 | 2006 | 189 | 0.260 |
Why?
|
| Mass Screening | 4 | 2012 | 427 | 0.250 |
Why?
|
| Aged, 80 and over | 10 | 2019 | 2333 | 0.250 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 207 | 0.250 |
Why?
|
| Texas | 9 | 2010 | 299 | 0.240 |
Why?
|
| Socioeconomic Factors | 4 | 2006 | 1003 | 0.240 |
Why?
|
| Benzodiazepines | 1 | 2023 | 13 | 0.240 |
Why?
|
| Caribbean Region | 5 | 2023 | 63 | 0.240 |
Why?
|
| Hospital Mortality | 1 | 2005 | 183 | 0.240 |
Why?
|
| Occult Blood | 1 | 2023 | 25 | 0.230 |
Why?
|
| Cytogenetics | 1 | 2022 | 3 | 0.230 |
Why?
|
| Civil Defense | 1 | 2023 | 10 | 0.230 |
Why?
|
| Prognosis | 3 | 2022 | 707 | 0.220 |
Why?
|
| Cervix Uteri | 2 | 2013 | 43 | 0.220 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 38 | 0.220 |
Why?
|
| Sexual Behavior | 4 | 2011 | 587 | 0.220 |
Why?
|
| Genetic Markers | 1 | 2022 | 118 | 0.220 |
Why?
|
| Sex Factors | 4 | 2014 | 859 | 0.220 |
Why?
|
| Quality of Life | 3 | 2021 | 459 | 0.210 |
Why?
|
| Cyclonic Storms | 1 | 2023 | 62 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 1 | 2022 | 187 | 0.200 |
Why?
|
| Agriculture | 3 | 2005 | 45 | 0.200 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 446 | 0.200 |
Why?
|
| Recombinant Proteins | 1 | 2022 | 485 | 0.200 |
Why?
|
| Vaccination | 1 | 2022 | 259 | 0.190 |
Why?
|
| Population Surveillance | 2 | 2019 | 231 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 178 | 0.190 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 188 | 0.180 |
Why?
|
| Prevalence | 3 | 2018 | 1425 | 0.180 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 151 | 0.180 |
Why?
|
| Social Class | 5 | 2011 | 228 | 0.170 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 92 | 0.170 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 36 | 0.170 |
Why?
|
| Capacity Building | 1 | 2019 | 78 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 36 | 0.160 |
Why?
|
| Mammography | 4 | 2009 | 176 | 0.160 |
Why?
|
| Survival Rate | 5 | 2021 | 310 | 0.160 |
Why?
|
| Health Services Misuse | 1 | 2017 | 12 | 0.160 |
Why?
|
| Oncogene Proteins, Viral | 3 | 2005 | 25 | 0.150 |
Why?
|
| Logistic Models | 7 | 2015 | 894 | 0.150 |
Why?
|
| Age Factors | 4 | 2014 | 1007 | 0.150 |
Why?
|
| Insulin Resistance | 2 | 2011 | 177 | 0.150 |
Why?
|
| Case-Control Studies | 8 | 2006 | 1056 | 0.140 |
Why?
|
| Poverty | 2 | 2009 | 316 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 181 | 0.140 |
Why?
|
| Public Health | 1 | 2019 | 348 | 0.140 |
Why?
|
| Uterine Cervical Diseases | 2 | 2013 | 14 | 0.140 |
Why?
|
| Mexican Americans | 2 | 2009 | 177 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2005 | 133 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2019 | 371 | 0.130 |
Why?
|
| Repressor Proteins | 3 | 2005 | 226 | 0.130 |
Why?
|
| Protective Clothing | 1 | 2014 | 7 | 0.130 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 570 | 0.120 |
Why?
|
| Unsafe Sex | 2 | 2012 | 161 | 0.120 |
Why?
|
| Anus Diseases | 1 | 2013 | 17 | 0.120 |
Why?
|
| Anal Canal | 1 | 2012 | 28 | 0.110 |
Why?
|
| Health Surveys | 1 | 2014 | 358 | 0.110 |
Why?
|
| Cultural Characteristics | 3 | 2011 | 119 | 0.110 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 214 | 0.110 |
Why?
|
| Latin America | 2 | 2023 | 41 | 0.100 |
Why?
|
| Biotechnology | 1 | 2011 | 15 | 0.100 |
Why?
|
| Insurance, Health | 3 | 2022 | 120 | 0.100 |
Why?
|
| Health Promotion | 2 | 2009 | 588 | 0.100 |
Why?
|
| Consumer Health Information | 1 | 2011 | 22 | 0.100 |
Why?
|
| Marketing | 1 | 2011 | 38 | 0.100 |
Why?
|
| User-Computer Interface | 1 | 2011 | 62 | 0.100 |
Why?
|
| Self Care | 1 | 2012 | 150 | 0.100 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 269 | 0.100 |
Why?
|
| Comprehensive Health Care | 1 | 2010 | 8 | 0.100 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2010 | 8 | 0.100 |
Why?
|
| Genotype | 1 | 2013 | 641 | 0.100 |
Why?
|
| Self Efficacy | 2 | 2009 | 173 | 0.090 |
Why?
|
| Evidence-Based Practice | 1 | 2010 | 41 | 0.090 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 176 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2014 | 322 | 0.090 |
Why?
|
| Human papillomavirus 16 | 2 | 2007 | 34 | 0.090 |
Why?
|
| Genital Neoplasms, Male | 1 | 2008 | 2 | 0.090 |
Why?
|
| Genital Diseases, Male | 1 | 2008 | 2 | 0.090 |
Why?
|
| Women's Health | 2 | 2006 | 135 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 176 | 0.080 |
Why?
|
| Condylomata Acuminata | 1 | 2008 | 6 | 0.080 |
Why?
|
| Ovarian Neoplasms | 2 | 2002 | 303 | 0.080 |
Why?
|
| Trust | 1 | 2010 | 119 | 0.080 |
Why?
|
| Educational Status | 1 | 2010 | 295 | 0.080 |
Why?
|
| Health Education | 1 | 2011 | 304 | 0.080 |
Why?
|
| Internet | 1 | 2010 | 204 | 0.080 |
Why?
|
| Ploidies | 1 | 2007 | 5 | 0.080 |
Why?
|
| Qualitative Research | 1 | 2010 | 393 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 225 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2004 | 22 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2007 | 1152 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 56 | 0.080 |
Why?
|
| Cross-Sectional Studies | 5 | 2015 | 2561 | 0.070 |
Why?
|
| Carcinoma | 1 | 2007 | 94 | 0.070 |
Why?
|
| Chromatin | 1 | 2007 | 164 | 0.070 |
Why?
|
| Adiponectin | 1 | 2006 | 52 | 0.070 |
Why?
|
| Patient Participation | 1 | 2006 | 68 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2006 | 141 | 0.070 |
Why?
|
| Physician-Patient Relations | 1 | 2006 | 118 | 0.070 |
Why?
|
| Survivors | 1 | 2006 | 126 | 0.070 |
Why?
|
| Air Pollutants, Occupational | 1 | 2005 | 9 | 0.070 |
Why?
|
| Transients and Migrants | 1 | 2005 | 25 | 0.070 |
Why?
|
| Wood | 1 | 2005 | 16 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2005 | 522 | 0.060 |
Why?
|
| Women | 1 | 2005 | 26 | 0.060 |
Why?
|
| Dust | 1 | 2005 | 51 | 0.060 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2004 | 22 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2004 | 10 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2005 | 136 | 0.060 |
Why?
|
| Vulvar Neoplasms | 1 | 2004 | 12 | 0.060 |
Why?
|
| Odds Ratio | 4 | 2010 | 517 | 0.060 |
Why?
|
| Acculturation | 1 | 2005 | 172 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2012 | 628 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2010 | 727 | 0.060 |
Why?
|
| Lymph Nodes | 1 | 2004 | 67 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2005 | 528 | 0.060 |
Why?
|
| Antibodies, Viral | 1 | 2005 | 252 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2005 | 298 | 0.060 |
Why?
|
| Guam | 1 | 2023 | 76 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2003 | 66 | 0.060 |
Why?
|
| Research Design | 1 | 2005 | 292 | 0.060 |
Why?
|
| Efficiency | 1 | 2003 | 17 | 0.060 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2023 | 52 | 0.060 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2002 | 3 | 0.060 |
Why?
|
| Gynecology | 1 | 2003 | 31 | 0.060 |
Why?
|
| Menopause | 1 | 2003 | 54 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2003 | 53 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 81 | 0.060 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2002 | 33 | 0.050 |
Why?
|
| Adenofibroma | 1 | 2002 | 1 | 0.050 |
Why?
|
| Thyroid Diseases | 1 | 2002 | 4 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 114 | 0.050 |
Why?
|
| Confidence Intervals | 3 | 2010 | 151 | 0.050 |
Why?
|
| Mentors | 1 | 2003 | 111 | 0.050 |
Why?
|
| Emotions | 1 | 2023 | 204 | 0.050 |
Why?
|
| Data Collection | 2 | 2015 | 188 | 0.050 |
Why?
|
| International Cooperation | 1 | 2019 | 44 | 0.050 |
Why?
|
| Pamphlets | 1 | 2019 | 27 | 0.050 |
Why?
|
| Medical Tourism | 1 | 2019 | 4 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2023 | 469 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2006 | 445 | 0.040 |
Why?
|
| International Agencies | 1 | 2019 | 5 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2019 | 26 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2010 | 212 | 0.040 |
Why?
|
| Developing Countries | 1 | 2019 | 97 | 0.040 |
Why?
|
| Cause of Death | 1 | 2019 | 154 | 0.040 |
Why?
|
| Tumor Virus Infections | 2 | 2010 | 25 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 370 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 16 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 18 | 0.040 |
Why?
|
| Age Distribution | 2 | 2010 | 223 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 254 | 0.040 |
Why?
|
| Diet | 1 | 2003 | 747 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2009 | 356 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2017 | 288 | 0.030 |
Why?
|
| Pregnancy | 2 | 2011 | 1503 | 0.030 |
Why?
|
| California | 2 | 2009 | 436 | 0.030 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2005 | 11 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2007 | 424 | 0.030 |
Why?
|
| Insurance Coverage | 2 | 2005 | 99 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 639 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2011 | 775 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 196 | 0.030 |
Why?
|
| Sentinel Surveillance | 1 | 2014 | 20 | 0.030 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 228 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2014 | 79 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2010 | 1422 | 0.030 |
Why?
|
| Mexico | 2 | 2005 | 223 | 0.030 |
Why?
|
| Child | 2 | 2011 | 2875 | 0.030 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 61 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2015 | 435 | 0.030 |
Why?
|
| Comorbidity | 1 | 2014 | 606 | 0.030 |
Why?
|
| Multimedia | 1 | 2011 | 16 | 0.030 |
Why?
|
| Coitus | 1 | 2011 | 13 | 0.030 |
Why?
|
| Pregnancy in Adolescence | 1 | 2011 | 33 | 0.030 |
Why?
|
| Parity | 1 | 2011 | 46 | 0.020 |
Why?
|
| Oklahoma | 1 | 2010 | 24 | 0.020 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2010 | 12 | 0.020 |
Why?
|
| Alaska | 1 | 2010 | 52 | 0.020 |
Why?
|
| Community Health Planning | 1 | 2010 | 35 | 0.020 |
Why?
|
| Micronesia | 1 | 2010 | 87 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2010 | 33 | 0.020 |
Why?
|
| Population Groups | 1 | 2010 | 56 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 204 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 316 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 73 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 429 | 0.020 |
Why?
|
| Schools | 1 | 2011 | 229 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 237 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2011 | 165 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2008 | 31 | 0.020 |
Why?
|
| Indians, North American | 1 | 2010 | 145 | 0.020 |
Why?
|
| Human papillomavirus 18 | 1 | 2007 | 5 | 0.020 |
Why?
|
| Image Cytometry | 1 | 2007 | 6 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2011 | 308 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 171 | 0.020 |
Why?
|
| Anus Neoplasms | 1 | 2008 | 47 | 0.020 |
Why?
|
| Virus Integration | 1 | 2007 | 49 | 0.020 |
Why?
|
| Psychometrics | 1 | 2009 | 292 | 0.020 |
Why?
|
| Biopsy | 1 | 2007 | 151 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2011 | 1353 | 0.020 |
Why?
|
| Outpatients | 1 | 2006 | 33 | 0.020 |
Why?
|
| Hela Cells | 1 | 2007 | 344 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2006 | 49 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 430 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 1681 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2006 | 69 | 0.020 |
Why?
|
| New Mexico | 1 | 2005 | 31 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2007 | 287 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 605 | 0.020 |
Why?
|
| Infant | 1 | 2009 | 1014 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2005 | 34 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2005 | 58 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 465 | 0.020 |
Why?
|
| Endometrium | 1 | 2006 | 57 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2005 | 50 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2005 | 9 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2005 | 68 | 0.020 |
Why?
|
| Breast Self-Examination | 1 | 2005 | 10 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 423 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2005 | 59 | 0.020 |
Why?
|
| Physical Examination | 1 | 2005 | 40 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2009 | 1318 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2005 | 136 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2006 | 202 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 232 | 0.020 |
Why?
|
| Rosaniline Dyes | 1 | 2004 | 2 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 165 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2004 | 25 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 2003 | 13 | 0.020 |
Why?
|
| Social Support | 1 | 2006 | 356 | 0.010 |
Why?
|
| Rural Population | 1 | 2005 | 253 | 0.010 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2003 | 9 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2003 | 26 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 932 | 0.010 |
Why?
|
| Obesity | 1 | 2011 | 965 | 0.010 |
Why?
|
| Dietary Fiber | 1 | 2003 | 42 | 0.010 |
Why?
|
| Risk | 1 | 2003 | 256 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2003 | 323 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 1124 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2002 | 14 | 0.010 |
Why?
|
| Vitamin E | 1 | 2003 | 56 | 0.010 |
Why?
|
| Diet Surveys | 1 | 2003 | 96 | 0.010 |
Why?
|
| Carotenoids | 1 | 2003 | 70 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 555 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 1490 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 608 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 200 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 964 | 0.010 |
Why?
|
| Hypertension | 1 | 2006 | 770 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2003 | 418 | 0.010 |
Why?
|
| Smoking | 1 | 2005 | 903 | 0.010 |
Why?
|
| HIV Infections | 1 | 2011 | 2207 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 5668 | 0.010 |
Why?
|
| Animals | 1 | 2003 | 14307 | 0.000 |
Why?
|
Tortolero-Luna's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(309)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(14)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_